FDA approval of MDMA for PTSD and psilocybin for depression is anticipated within the next 24 months, according to a letter from the Department of Health and Human Services.
The department is also considering starting a federal task force dedicated to addressing complex issues surrounding psychedelics such as harm reduction and safety.
“Too many Americans are suffering from mental health and substance use issues, which have been exacerbated by the ongoing COVID-19 pandemic, and that we must explore the potential of psychedelic-assisted therapies to address this crisis,” the letter explains.